A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers

References

• Abbott NJ. 2002. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200:629–638.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. 2005. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 25:5–23.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. 2010. Structure and function of the blood-brain barrier. Neurobiol Dis 37:13–25.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. 1999. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 39:105–116.
   PubMed Web of Science ®Google Scholar
• Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. 2004. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735–743.
   PubMed Web of Science ®Google Scholar
• Bali V, Ali M, Ali J. 2010. Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. J Drug Target Article online in advance of print - DOI 10.3109/10611860903548362.
   Google Scholar
• Barchet TM, Amiji MM. 2009. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 6:211–225.
   PubMed Web of Science ®Google Scholar
• Beduneau A, Saulnier P, Benoit JP. 2007. Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947–4967.
   PubMed Web of Science ®Google Scholar
• Begley DJ, Brightman MW. 2003. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 61:39–78.
   PubMedGoogle Scholar
• Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3–9.
   PubMed Web of Science ®Google Scholar
• Brasnjevica I, Steinbuscha H, Schmitza C, Martinez-Martinez P. 2009. Delivery of peptide and protein drugs over the blood brain barrier. Prog Neurobiol 87:212–251.
   PubMedGoogle Scholar
• Buggins T, Dickinson P, Taylor G. 2007. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 59:1482–1503.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Cornford EM. 1985. The blood brain barrier, a dynamic regulatory interface. Mol Physiol 7:219–259.
   Google Scholar
• Danielson PB. 2002. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561–597.
   PubMed Web of Science ®Google Scholar
• Dean M, Annilo T. 2005. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 6:123–142.
   PubMed Web of Science ®Google Scholar
• Deeley RG, Westlake C, Cole SP. 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899.
   PubMed Web of Science ®Google Scholar
• Deli MA. 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788:892–910.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R. 2002. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339–348.
   PubMed Web of Science ®Google Scholar
• Edmond J. 2001. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 16:181–193; discussion 215–221.
   PubMed Web of Science ®Google Scholar
• Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. 2004. The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol Pharmacol 65:479–487.
   PubMed Web of Science ®Google Scholar
• Eyal S, Hsiao P, Unadkat JD. 2009. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80–104.
   PubMed Web of Science ®Google Scholar
• Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309–1318.
   PubMed Web of Science ®Google Scholar
• Ferrari M. 2005. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171.
   PubMed Web of Science ®Google Scholar
• Florence AT. 2005. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2:75–81.
   Google Scholar
• Fricker G, Miller DS. 2004. Modulation of drug transporters at the blood-brain barrier. Pharmacology 70:169–176.
   PubMed Web of Science ®Google Scholar
• Ganta S, Amiji M. 2009. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6:928–939.
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Amiji M. 2010. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci Article online in advance of print - DOI: 10.1002/jps.22157.
   Google Scholar
• Ganta S, Devalapally H, Baguley B, Garg S, Amiji M. 2008a. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol 4:165–173.
   Web of Science ®Google Scholar
• Ganta S, Paxton JW, Baguley BC, Garg S. 2008b. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm 360:115–121.
   PubMed Web of Science ®Google Scholar
• Ganta S, Sharma P, Garg S. 2008c. Permeability assessment. New York: Wiley-Interscience.
   Google Scholar
• Ganta S, Sharma P, Paxton JW, Baguley BC, Garg S. 2010. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target 18(2): 125–133.
   PubMedGoogle Scholar
• Gindy ME, Prud'homme RK. 2009. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 6:865–878.
   PubMed Web of Science ®Google Scholar
• Goldberg M, Gomez-Orellana I. 2003. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2:289–295.
   PubMed Web of Science ®Google Scholar
• Golden PL, Pollack GM. 2003. Blood-brain barrier efflux transport. J Pharm Sci 92:1739–1753.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Gray JH, Owen RP, Giacomini KM. 2004. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447:728–734.
   PubMed Web of Science ®Google Scholar
• Greish K. 2007. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15:457–464.
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564–1569.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665.
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Egleton RD. 2008. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol 80:277–309.
   PubMedGoogle Scholar
• Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. 2004. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465–468.
   PubMed Web of Science ®Google Scholar
• Hochman J, Artursson P. 1994. Mechanism of absorption enhancement and tight junction regulation. J Control Release 29:253–267.
   Web of Science ®Google Scholar
• Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A. 2008. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134:597–607.
   PubMed Web of Science ®Google Scholar
• Jabr-Milane LS, Van Vlerken LE, Yadav S, Amiji MM. 2008. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34:592–602.
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Summerfield S. 2010. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis 37:33–37.
   PubMed Web of Science ®Google Scholar
• Jones PM, George AM. 2004. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61:682–699.
   PubMed Web of Science ®Google Scholar
• Kim KY. 2007. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3:103–110.
   PubMed Web of Science ®Google Scholar
• Koning GA, Krijger GC. 2007. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 7:425–440.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. 2005. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73–85.
   PubMedGoogle Scholar
• La Guardia M, Giammanco S, Di Majo D, Tabacchi G, Tripoli E, Giammanco M. 2005. Omega 3 fatty acids: biological activity and effects on human health. Panminerva Med 47:245–257.
   PubMedGoogle Scholar
• Lennernas H, Abrahamsson B. 2005. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 57:273–285.
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. 2002. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240:95–102.
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. 2005a. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86–98.
   PubMedGoogle Scholar
• Loscher W, Potschka H. 2005b. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22–76.
   PubMed Web of Science ®Google Scholar
• Luurtsema G, De Lange EC, Lammertsma AA, Franssen EJ. 2004. Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol Imaging Biol 6:306–318.
   PubMed Web of Science ®Google Scholar
• Madhusudhan B, Rambhau D, Apte SS, Gopinath D. 2007. 1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice. J Drug Target 15:154–161.
   PubMed Web of Science ®Google Scholar
• Malingre MM, Beijnen JH, Schellens JH. 2001. Oral delivery of taxanes. Invest New Drugs 19:155–162.
   PubMed Web of Science ®Google Scholar
• Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J. 2008. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 324:558–567.
   PubMed Web of Science ®Google Scholar
• Mossink MH, Van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. 2003. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22:7458–7467.
   PubMed Web of Science ®Google Scholar
• Nies AT. 2007. The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254:11–29.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. 2001. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55–64.
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Liu S, Moscow JA, Mumper RJ. 2003. Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. Bioconjug Chem 14:404–11.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 1999. Blood-brain barrier biology and methodology. J Neurovirol 5:556–569.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2002. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131–139.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discov Today 12:54–61.
   PubMed Web of Science ®Google Scholar
• Patlolla RR, Vobalaboina V. 2008. Folate-targeted etoposide-encapsulated lipid nanospheres. J Drug Target 16:269–275.
   PubMed Web of Science ®Google Scholar
• Pierre K, Pellerin L. 2005. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 94:1–14.
   PubMed Web of Science ®Google Scholar
• Potschka H. 2010. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 125:118–127.
   PubMedGoogle Scholar
• Rajagopal A, Simon SM. 2003. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14:3389–3399.
   PubMed Web of Science ®Google Scholar
• Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hladky SB. 2005. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem 94:1420–1426.
   PubMed Web of Science ®Google Scholar
• Salama N, Eddington N, Fasano A. 2006. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58:15–28.
   PubMed Web of Science ®Google Scholar
• Sarker DK. 2005. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2:297–310.
   PubMedGoogle Scholar
• Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. 2000. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550–556.
   PubMed Web of Science ®Google Scholar
• Seelig A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252–261.
   PubMedGoogle Scholar
• Seelig A, Landwojtowicz E. 2000. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31–40.
   PubMed Web of Science ®Google Scholar
• Shimazawa M, Nakajima Y, Mashima Y, Hara H. 2009. Docosahexaenoic acid (DHA) has neuroprotective effects against oxidative stress in retinal ganglion cells. Brain Res 1251:269–275.
   PubMed Web of Science ®Google Scholar
• Soontornmalai A, Vlaming ML, Fritschy JM. 2006. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 138:159–169.
   PubMed Web of Science ®Google Scholar
• Stevenson BR. 1998. The tight junction: morphology to molecules. Annu Rev Cell Dev Biol 14:89–109.
   PubMed Web of Science ®Google Scholar
• Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. 2004. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 24:397–404.
   PubMed Web of Science ®Google Scholar
• Taogoshi T, Nomura A, Murakami T, Nagai J, Takano M. 2005. Transport of prostaglandin E1 across the blood-brain barrier in rats. J Pharm Pharmacol 57:61–66.
   PubMed Web of Science ®Google Scholar
• Thummel K, Kunze K, Shen D. 1997. Enzyme catalyzed processes of first pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99–127.
   PubMed Web of Science ®Google Scholar
• Tiwari S. 2007. Nanoemulsion formulations for tumor-targeted delivery. In: Mansoor M. Amiji, editor. Nanotechnology for cancer therapy. New York: CRC Press.
   Google Scholar
• Tiwari S, Amiji M. 2006a. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 9:3215–3221.
   Google Scholar
• Tiwari S, Tan Y-M, Amiji M. 2006. Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery. J Biomed Nanotechnol 2:217–224.
   Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. 2006b. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219–232.
   PubMedGoogle Scholar
• Torchilin VP. 2002. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev 54:235–252.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2006. Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–1555.
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Van Tellingen O, Van Der Valk MA, Rozenhart M, Beijnen JH. 1998. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293–2297.
   PubMed Web of Science ®Google Scholar
• Varatharajana L, Thomas S. 2009. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recomendations for further research. Antiviral Res 82:A99–A109.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Amiji MM. 2008. Improved oral bioavailability and brain transport of saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm 347:93–101.
   PubMed Web of Science ®Google Scholar
• Wickline SA, Lanza GM. 2003. Nanotechnology for molecular imaging and targeted therapy. Circulation 107:1092–1095.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A. 2002. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323–337.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. 2001. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett 307:77–80.
   PubMed Web of Science ®Google Scholar
• Yang SC, Benita S. 2000. Enhanced absorption and drug targeting by positively charged submicron emulsions. Drug Develop Res 50:476–486.
   Web of Science ®Google Scholar
• Zhang W, Tan TM, Lim LY. 2007. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110–115.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159–168.
   PubMed Web of Science ®Google Scholar